

FAD

Metastatic HER2+ disease: how today's tools help us improve the future of our patients

May 22,
2024
2 pm

SCIENTIFIC MANAGERS

*Andrea Botticelli
Carmen Criscitiello
Carmine De Angelis
Maria Vittoria Dieci*



RATIONAL

Breast cancer represents the most frequent malignancy in the female sex and the leading cause of cancer-related death in women. Recent years have been marked by major advances in the treatment of metastatic disease that have led to a significant improvement in survival, thanks to a strategy increasingly focused on personalization.

In particular, scientific advances in HER2+ disease have improved outcomes for these patients but increased survival remains a primary goal for metastatic stage patients.

The goal of this project is, in addition to scientific updates on the possibilities offered by new treatment options, to identify what issues need to be addressed within the care pathway of metastatic HER2+ patients in order to understand how to optimize their management by sharing experiences from diverse and international clinical settings.

Indeed, the management of HER2+ metastatic patients requires an integrated approach that takes into account the complexity of the disease and involves a variety of professionals and tools, such as RWE (real world evidence) and SDM (shared decision making), to ensure the best possible outcome in terms of survival and well-being.

PROGRAM

14.00 - 14.05 Introduction and course objectives – *M.V. Dieci, C. De Angelis*

14.05 - 14.15 Discussion of survey results – *A. Botticelli, C. Criscitiello, C. De Angelis, M.V. Dieci*

SESSION I: TODAY

14.15 - 14.35 Therapeutic highlights in the treatment of patients with Her2+ metastatic breast cancer: the evolution of therapeutic sequences – *C. Criscitiello*

14.35 - 14.55 The importance of real-world data and patient reported outcome – *M. Di Maio*

14.55 - 15.15 Lecture: Optimal management of patients with brain metastases – *G. Griguolo*

15.15 - 15.55 Round table: clinical scenarios and optimal therapeutic strategies in patients with mBC
G. Griguolo, I. Meattini, F. DiMeco – Moderano: C. Criscitiello, A. Botticelli

SESSION II: TOMORROW

15.55 - 16.15 Lecture: the future of treatments: new drugs and combinations, leading ADCs? – *F. André*

16.15 - 16.30 The Digital Pathology and AI: the future of breast cancer pathology – *N. Fusco*

16.30 - 16.45 Possible applications of AI in breast cancer radiology – *D. La Torre*

16.45 - 17.15 Round table: Sharing decision making and the dialogue with patients – *R. D'Antona, G. Arpino, A. Toss, N. Fusco Moderano: M.V. Dieci, C. De Angelis*

17.15 - 17.30 Sum up and closing – *A. Botticelli, C. Criscitiello*

SCIENTIFIC MANAGERS

Andrea Botticelli

Assistant Professor Sapienza Università di Roma, Coordinatore Breast Unit Policlinico Umberto I Roma

Carmen Criscitiello

Division of New Drug Development for Innovative Therapies, IEO European Institute of Oncology IRCCS, Milan, Italy. Researcher of Medical Oncology. Department of Oncology and Hemato-Oncology, University of Milan

Carmine De Angelis

Department of Clinical Medicine and Surgery, University Federico II, Naples

Maria Vittoria Dieci

MD, is Associate Professor of Medical Oncology at the University of Padova, and attending physician at the Division of Medical Oncology 2 of the Istituto Oncologico Veneto in Padova

FACULTY

Fabrice André

Director of Research, Gustave Roussy Institute, 94805 Villejuif Cedex, France

Grazia Arpino

Department of Clinical Medicine and Surgery, Federico II University of Naples

Rosanna D'Antona

President of Europa Donna Italia

Massimo Di Maio

Department of Oncology, University of Turin

Francesco DiMeco

Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Department of Oncology and Onco-Hematology, Università di Milano, Milan, Italy, Department of Neurological Surgery, Johns Hopkins Medical School, Baltimore, USA

Nicola Fusco

Director of the IEO Division of Pathologic Anatomy and Associate Professor of Pathologic Anatomy at the Department of Oncology and Hemato-Oncology, University of Milan

Gaia Griguolo

Department of Surgery, Oncology and Gastroenterology, University of Padua

Davide La Torre

Professor of Artificial Intelligence and Quantitative Methods at the PRISM Research Center of SKEMA Business School, France

Icro Meattini

Department of Experimental and Clinical Biomedical Sciences M Serio, University of Florence, Florence, Italy; Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence

Angela Toss

Department of Oncology and Hematology, University Hospital of Modena



La FAD Sincrona è inserita nella lista degli eventi definitivi ECM nel programma formativo 2024 del Provider. Al superamento del corso **“Metastatic HER2+ disease: how today's tools help us improve the future of our patients”** saranno attribuiti **n. 4,5 Crediti formativi ECM** per le seguenti figure professionali: **Medico Chirurgo** (Disciplina: Oncologia, Anatomia Patologica, Chirurgia Generale, Radioterapia, Radiodiagnostica), **Biologo**.

Numero Partecipanti: 500

L'assegnazione dei crediti formativi è subordinata alla partecipazione effettiva dell'intero programma e al superamento della verifica di apprendimento.

COME REGISTRARSI

- Accedere al sito www.medicacem.it
- In caso di primo accesso cliccare su AREA RISERVATA nella barra in alto della homepage del sito e, successivamente, sulla voce Registrati completando il form con i propri dati.
- Riceverai una mail di conferma automatica all'indirizzo specificato.
- Effettua ora login/accesso alla piattaforma con i tuoi dati personali e iscriviti al corso **“Metastatic HER2+ disease: how today's tools help us improve the future of our patients”**.
- Per completare l'iscrizione, è necessario premere “Invia”.
- Si consiglia di preiscriversi qualche giorno prima. Una volta terminato il percorso formativo, il discente dovrà compilare i questionari di valutazione e di qualità, necessari per l'ottenimento dei crediti. I crediti verranno erogati a fronte di una effettiva presenza ad almeno il 90% della durata complessiva dell'intera attività formativa e con il superamento della prova di apprendimento con almeno il 75% delle risposte corrette.
- Per assistenza tecnica, cliccare il box Assistenza nella homepage del sito www.medicacem.it e completare il form.



Progetto realizzato con il supporto non condizionante di:



Provider ECM ID 2157
REGISTRAZIONE IN AREA RISERVATA
Medica - Edizione Offensiva e Difensiva del Corso Unico Stato
Dopo il corso Area RISERVATA
P.le G. Cesare, 10 - 00187 Roma
Tel. 06 70881222
Fax 06 70881200
info@medicaem.it
www.medicacem.it

EDITORIA E DIFFUSIONE SCIENTIFICA